Literature DB >> 17558561

The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis.

Silvia Colucci1, Giacomina Brunetti, Francesco Paolo Cantatore, Angela Oranger, Giorgio Mori, Paolo Pignataro, Roberto Tamma, Felice Roberto Grassi, Alberta Zallone, Maria Grano.   

Abstract

The number and activity of osteoclasts (OCs) are critical for maintaining normal bone turnover. The number is determined by the rates of cell differentiation and death. TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, induces apoptosis by interacting with its death receptors, (DR4, DR5). However, its activity can be modulated by two decoy receptors, (DcR1 and DcR2). In this paper we show that TRAIL treatment causes reduced OC viability as well as an increased apoptotic OC number. Loss of nuclei integrity and derangement of the actin microfilament were also induced by TRAIL in OCs. Moreover, we demonstrated the expression of all TRAIL receptors in both precursors and differentiated OCs, and the upregulation of DR5 during OC differentiation. Interestingly, DcR2 was upregulated in the early stage of osteoclastogenesis and downregulated at the end of the differentiation process. We showed that DR5, upregulated by TRAIL, could be the mediator of TRAIL-induced OC apoptosis, since the addition of anti-DR5 neutralizing antibodies restores the OC viability previously reduced by TRAIL. Furthermore, the intracellular pathway induced by TRAIL in OCs involves caspase-8 and Bid activation. In conclusion, our data highlight an important role for the TRAIL/TRAIL receptor system in the regulation of OC apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17558561     DOI: 10.1007/s10495-007-0095-3

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  18 in total

Review 1.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

2.  Interleukin-15-activated natural killer cells kill autologous osteoclasts via LFA-1, DNAM-1 and TRAIL, and inhibit osteoclast-mediated bone erosion in vitro.

Authors:  Shan Feng; Suzi H Madsen; Natasja N Viller; Anita V Neutzsky-Wulff; Carsten Geisler; Lars Karlsson; Kalle Söderström
Journal:  Immunology       Date:  2015-05-19       Impact factor: 7.397

3.  TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.

Authors:  Hirofumi Tenshin; Jumpei Teramachi; Asuka Oda; Ryota Amachi; Masahiro Hiasa; Ariunzaya Bat-Erdene; Keiichiro Watanabe; Masami Iwasa; Takeshi Harada; Shiro Fujii; Kumiko Kagawa; Kimiko Sogabe; Shingen Nakamura; Hirokazu Miki; Kiyoe Kurahashi; Sumiko Yoshida; Kenichi Aihara; Itsuro Endo; Eiji Tanaka; Toshio Matsumoto; Masahiro Abe
Journal:  Blood Adv       Date:  2017-10-26

4.  Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation.

Authors:  Hu Xiaowen; Sun Yi
Journal:  Mol Biol Rep       Date:  2012-06-17       Impact factor: 2.316

Review 5.  Optimizing intracellular signaling domains for CAR NK cells in HIV immunotherapy: a comprehensive review.

Authors:  Giorgio Zenere; Omalla Allan Olwenyi; Siddappa N Byrareddy; Stephen E Braun
Journal:  Drug Discov Today       Date:  2019-02-13       Impact factor: 7.851

6.  Selective TRAIL-triggered apoptosis due to overexpression of TRAIL death receptor 5 (DR5) in P-glycoprotein-bearing multidrug resistant CEM/VBL1000 human leukemia cells.

Authors:  Soo-Jung Park; Khadijeh Bijangi-Vishehsaraei; Ahmad R Safa
Journal:  Int J Biochem Mol Biol       Date:  2010-07-18

Review 7.  Interaction of staphylococci with bone.

Authors:  John A Wright; Sean P Nair
Journal:  Int J Med Microbiol       Date:  2009-11-03       Impact factor: 3.473

8.  Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim.

Authors:  Nicolas Houde; Estelle Chamoux; Martine Bisson; Sophie Roux
Journal:  J Biol Chem       Date:  2009-07-01       Impact factor: 5.157

9.  Immunology of Gut-Bone Signaling.

Authors:  Fraser L Collins; Jonathan D Schepper; Naiomy Deliz Rios-Arce; Michael D Steury; Ho Jun Kang; Heather Mallin; Daniel Schoenherr; Glen Camfield; Saima Chishti; Laura R McCabe; Narayanan Parameswaran
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 10.  Periodontal disease: linking the primary inflammation to bone loss.

Authors:  Adriana Di Benedetto; Isabella Gigante; Silvia Colucci; Maria Grano
Journal:  Clin Dev Immunol       Date:  2013-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.